Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

For treating patients with RAVs from prior DAA failure, the duration of the regimen used for re-treatment is much less consequential than its success rate. I.e., the one thing you absolutely want to avoid is a second treatment failure, possibly leaving the uncured patient with RAVs to overcome.

Even for treatment-naive patients, almost everyone who follows this field of medicine thinks that 4-week regimens are too short. 6-week regimens might be possible for the easiest-to-treat patients, but cutting out only 2 weeks (relative to an 8-week regimen) may not be worth the increased risk of relapse.